Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.69 |
| ▸ | BHMT | Q93088 | 1/20 | 0.46 |
| ▸ | ARG2 | P78540 | 4/20 | 0.44 |
| ▸ | ARG1 | P05089 | 3/20 | 0.44 |
| ▸ | NOS2 | P35228 | 5/20 | 0.44 |
| ▸ | NOS1 | P29475 | 4/20 | 0.44 |
| ▸ | NOS3 | P29474 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL16099029 | 1.00 | GSR (0.69) | GSRBHMTARG2ARG1NOS2 | |
| Ornithine Aketoglutarate SCHEMBL16097781 | 0.95 | GSR (0.60) | GSRBHMTARG2ARG1NOS2 | |
| Ornithine SCHEMBL16097782 | 0.95 | GSR (0.60) | GSRBHMTARG2ARG1NOS2 | |
| Lysine SCHEMBL4667085 | 0.87 | GSR (0.83) | GSRARG2ARG1NOS2NOS1 | |
| Lysine SCHEMBL4667086 | 0.87 | GSR (0.83) | GSRARG2ARG1NOS2NOS1 | |
| Lysine SCHEMBL17318095 | 0.86 | GSR (0.69) | GSRBHMTARG2ARG1NOS2 | |
| Lysine SCHEMBL17318093 | 0.86 | GSR (0.69) | GSRBHMTARG2ARG1NOS2 | |
| Lysine SCHEMBL7706799 | 0.85 | GSR (0.80) | GSRARG2ARG1NOS2NOS1 | |
| Lysine SCHEMBL18528930 | 0.85 | GSR (0.80) | GSRARG2ARG1NOS2NOS1 | |
| Lysine SCHEMBL20952564 | 0.85 | GSR (0.80) | GSRARG2ARG1NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11806328-B2 | Metabolic therapy for wound healing | UNIVERSITY OF SOUTH FLORIDA (US) | 2023-11-07 | — | — | US | claimed |
| US-20210093602-A1 | METABOLIC THERAPY FOR WOUND HEALING | UNIVERSITY OF SOUTH FLORIDA | 2021-04-01 | — | — | US | claimed |
| US-10864184-B1 | Metabolic therapy for wound healing | UNIVERSITY OF SOUTH FLORIDA (US) | 2020-12-15 | — | — | US | claimed |
| US-20200268701-A1 | COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS | UNIV SOUTH FLORIDA (US) | 2020-08-27 | — | — | US | claimed |
| US-10646462-B2 | Compositions and methods for producing elevated and sustained ketosis | UNIVERSITY OF SOUTH FLORIDA (US) | 2020-05-12 | — | — | US | claimed |
| WO-2019200132-A1 | COMPOSITIONS AND METHODS FOR SUPPLEMENTING THE DIET | Metabolic Recovery Systems, LLC (US) | 2019-10-17 | — | — | WO | claimed |
| US-20190313682-A1 | COMPOSITIONS AND METHODS FOR SUPPLEMENTING THE DIET | Metabolic Recovery Systems, LLC | 2019-10-17 | — | — | US | claimed |
| EP-2976073-B1 | COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS | UNIV SOUTH FLORIDA (US) | 2019-08-28 | — | — | EP | claimed |
| US-20180021281-A1 | LIPID FORMULATIONS CONTAINING BIOACTIVE FATTY ACIDS AND OTHER BIOACTIVE AGENTS | SCIADONICS, INC. | 2018-01-25 | — | — | US | claimed |
| WO-2018017667-A1 | LIPID FORMULATIONS CONTAINING BIOACTIVE FATTY ACIDS AND OTHER BIOACTIVE AGENTS | SCIADONICS, INC. (US) | 2018-01-25 | — | — | WO | claimed |
| US-20170266148-A1 | COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-09-21 | — | — | US | claimed |
| US-9675577-B2 | Compositions and methods for producing elevated and sustained ketosis | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-06-13 | — | — | US | claimed |
| US-20160067207-A1 | COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-03-10 | — | — | US | claimed |
| EP-2976073-A1 | COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS | University Of South Florida (US) | 2016-01-27 | — | — | EP | claimed |
| US-9138420-B2 | Compositions and methods for producing elevated and sustained ketosis | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-09-22 | — | — | US | claimed |
| US-20140350105-A1 | COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-11-27 | — | — | US | claimed |
| WO-2014153416-A1 | COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-09-25 | — | — | WO | claimed |
| US-20240226043-A1 | ADMINISTRATION OF R-BETA-HYDROXYBUTYRATE AND RELATED COMPOUNDS IN HUMANS | AXCESS GLOBAL SCIENCES, LLC | 2024-07-11 | — | — | US | disclosed |
| US-20140350105-A1 | COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-11-27 | — | — | US | disclosed |
| WO-2014153416-A1 | COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180021281-A1 | LIPID FORMULATIONS CONTAINING BIOACTIVE FATTY ACIDS AND OTHER BIOACTIVE AGENTS | FAAH, ELOVL1, DGKA | GSR 3037/4885BHMT 1320/4885ARG2 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.